AK
Akebia Therapeutics, Inc.
AKBA · NASDAQ
$0.97 -1.35% (-$0.01)
1M +15.49%
Market Cap $263.8M
P/E Ratio -
Div. Yield -
ROE 93.74%
Bulios Fair Price
$1.32
35.4% upside
Trenutna cena
$0.97
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica AKBA trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
78 /100
Cheap P/S 1.20x
P/B 10.54x
P/FCF 6.56x
Growth
22 /100
Declining Rev. growth 6.88%
Book val. growth 84.06%
EPS growth N/A
Profitability
50 /100
Moderate Gross margin 79.48%
Net margin 13.54%
FCF margin 18.37%
Quality
8 /100
Poor ROIC 7.54%
ROE 93.74%
Asset turnover 0.63x
Debt
22 /100
High Debt/Equity 2.16x
Current ratio 1.43x
Int. coverage -2.50x
Stability
12 /100
Unstable Beta 0.24x
Rev. volatility 42.90%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o AKBA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Butler
Employees
194
Headquarters
Cambridge
Prihajajoči dogodki
09 NOV.
Earnings
Upcoming earnings report